CN112739698A - 作为ahr调节剂的四氢嘧啶衍生物 - Google Patents

作为ahr调节剂的四氢嘧啶衍生物 Download PDF

Info

Publication number
CN112739698A
CN112739698A CN201980060477.XA CN201980060477A CN112739698A CN 112739698 A CN112739698 A CN 112739698A CN 201980060477 A CN201980060477 A CN 201980060477A CN 112739698 A CN112739698 A CN 112739698A
Authority
CN
China
Prior art keywords
compound
indol
ethyl
nmr
400mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980060477.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·梅特
J·R·希特轻丝
M·格雷厄姆
J·金安德伍德
P·V·索恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jaguar Therapeutics Ltd
Original Assignee
Jaguar Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jaguar Therapeutics Ltd filed Critical Jaguar Therapeutics Ltd
Publication of CN112739698A publication Critical patent/CN112739698A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980060477.XA 2018-08-24 2019-08-23 作为ahr调节剂的四氢嘧啶衍生物 Pending CN112739698A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201807244X 2018-08-24
SG10201807244X 2018-08-24
PCT/EP2019/072641 WO2020039093A1 (en) 2018-08-24 2019-08-23 Tetrahydropyridopyrimidine derivatives as ahr modulators

Publications (1)

Publication Number Publication Date
CN112739698A true CN112739698A (zh) 2021-04-30

Family

ID=67982013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980060477.XA Pending CN112739698A (zh) 2018-08-24 2019-08-23 作为ahr调节剂的四氢嘧啶衍生物

Country Status (14)

Country Link
US (1) US12221439B2 (https=)
EP (1) EP3841102B1 (https=)
JP (1) JP2021535213A (https=)
KR (1) KR20210049135A (https=)
CN (1) CN112739698A (https=)
AU (1) AU2019323714A1 (https=)
BR (1) BR112021003529A2 (https=)
CA (1) CA3110402A1 (https=)
IL (1) IL281023A (https=)
MX (1) MX2021002215A (https=)
PH (1) PH12021550382A1 (https=)
SG (1) SG11202101441SA (https=)
WO (1) WO2020039093A1 (https=)
ZA (1) ZA202100931B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
WO2021210970A1 (en) * 2020-04-17 2021-10-21 Dong-A St Co., Ltd. Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014558A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyramidine compounds as inhibitors of voltage-gated ion channels
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
WO2010059401A2 (en) * 2008-10-30 2010-05-27 Irm Llc Compounds that expand hematopoietic stem cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY159230A (en) 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
US8691827B2 (en) 2009-08-17 2014-04-08 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
BR112013002079B1 (pt) 2010-07-27 2021-09-14 Trustees Of Boston University Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
WO2016154110A1 (en) * 2015-03-20 2016-09-29 Cleave Biosciences, Inc. Companion diagnostic for p97 inhibitor therapy and methods of use thereof
CA3025227A1 (en) 2016-05-25 2017-11-30 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014558A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyramidine compounds as inhibitors of voltage-gated ion channels
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
WO2010059401A2 (en) * 2008-10-30 2010-05-27 Irm Llc Compounds that expand hematopoietic stem cells

Also Published As

Publication number Publication date
CA3110402A1 (en) 2020-02-27
WO2020039093A1 (en) 2020-02-27
EP3841102A1 (en) 2021-06-30
JP2021535213A (ja) 2021-12-16
US20210332041A1 (en) 2021-10-28
IL281023A (en) 2021-04-29
ZA202100931B (en) 2021-10-27
EP3841102B1 (en) 2022-09-14
MX2021002215A (es) 2021-07-15
KR20210049135A (ko) 2021-05-04
BR112021003529A2 (pt) 2021-05-18
AU2019323714A1 (en) 2021-03-25
US12221439B2 (en) 2025-02-11
PH12021550382A1 (en) 2021-12-13
SG11202101441SA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
CN112739698A (zh) 作为ahr调节剂的四氢嘧啶衍生物
US20240262842A1 (en) Small molecule inhibitors of kras g12c mutant
JP7639020B2 (ja) アリール炭化水素受容体モジュレーターとしてのピリドピリミジノン誘導体およびその使用
JP2018150358A (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
JP2022551299A (ja) Ｂｒｄ４阻害活性を有する化合物、その調製方法および用途
CN114302886A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
US12202816B2 (en) Compounds as NADPH oxidase inhibitors
US20230391769A1 (en) Substituted heterocyclic compounds and therapeutic uses thereof
AU2024321427A1 (en) Pharmaceutical compounds and compositions as c-kit kinase inhibitors
WO2025019309A2 (en) Compounds and compositions as c-kit kinase inhibitors
JP7417540B2 (ja) シクロアルカン－１，３－ジアミン誘導体
KR20220153595A (ko) AhR 신호전달의 조절에 유용한 피리도피리미딘 유도체
EP4396191B1 (en) Compounds useful in modulation of ahr signalling
HK40055989A (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
HK40055989B (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
KR20250073623A (ko) AhR 신호전달의 조절에 유용한 화합물
WO2023033742A1 (en) Compounds useful in modulation of ahr signalling
EA041908B1 (ru) Производные 1,7-нафтиридина и их применение в качестве ингибиторов cdk8/19
HK1258849B (zh) 三环pi3k抑制剂化合物及其使用方法
HK1258849A1 (zh) 三环pi3k抑制剂化合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210430

WD01 Invention patent application deemed withdrawn after publication